Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (NGR018)
This study is currently recruiting participants.
Verified January 2013
by MolMed S.p.A.
Study NCT01358071 Information provided by MolMed S.p.A.
First Received on May 19, 2011. Last Updated on January 28, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms by Site
Interventions listed in this trial
Pegylated liposomal doxorubicin
More general drug interventions related to this trial
Sponsors listed in this trial
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers